About Us - Board of Directors

John J. Delucca has served as a Director since January 2006.  Mr. Delucca was Executive Vice President and Chief Financial Officer of the REL Consultancy Group until his retirement in 2004. Prior to that, he served as Chief Financial Officer and Executive Vice President, Finance & Administration, of Coty, Inc., from 1999 to 2002.  Mr. Delucca is currently a Non-Executive Director and chairs the Audit Committees of ITC Deltacom, Enzo Biochem, Inc. and The Elliot Company.  He also serves as a Non-Executive Director and Deputy Chairman of the Audit Committee of British Energy PLC.  Mr. Delucca is chairman of  Endo’s Audit Committee and is a member of  Endo's Compensation Committee.

Michel de Rosen has served as a Director since April 2006.  Mr. de Rosen has served as the Chairman of the Board of Directors and Chief Executive Officer of ViroPharma Incorporated since September 2002, President and Chief Executive Officer since August 2000, and as a Director since May 2000. From 1993 to 1999, he held several key positions in Rhone-Poulenc Pharma and Rhone-Poulenc Rorer (now Sanofi-Aventis), including Chairman and Chief Executive Officer from May 1995 until December 1999.  He began his career at the French Ministry of Finance and subsequently served in several leading government positions.  He also served in various executive roles in industry prior to 1993.  Mr. de Rosen also is a Director of ABB Ltd.  Mr. de Rosen is a member of Endo’s Nominating and Governance Committee.

George F. Horner III has served as a Director since August 2006. Mr. Horner is President and Chief Executive Officer of Prestwick Pharmaceuticals, Inc. He was the President and Chief Executive Officer and a member of the Board of Directors of Vicuron Pharmaceuticals Inc. from 1996 until its acquisition by Pfizer Inc. in September 2005. Prior to joining Vicuron, he was Corporate Vice President of Ligand Pharmaceuticals from 1993 to 1995. He also served in a number of executive positions during his 17 years at Abbott Laboratories from 1976 to 1993, including President, Canada; Regional Director, Latin America; General Manager, Mexico; General Manager, Southern Africa Region; and Regional Manager, Southeast Asia. Mr. Horner began his career in the pharmaceutical industry at E.R. Squibb, Inc., where he served in a number of sales and product management positions. Mr. Horner is also a director of Prestwick Pharmaceuticals and Novexel SA. Mr. Horner is a member of Endo’s Audit Committee and Compensation Committee.

Michael Hyatt has served as a Director since July 2000.   Mr. Hyatt had been a Director of Algos Pharmaceutical Corporation since November 1996. For more than five years, he has been a Senior Managing Director of Bear Stearns & Co., Inc.   Mr. Hyatt is chairman of Endo's Compensation Committee and is a member of Endo's Nominating and Governance Committee.

Roger H. Kimmel has served as Chairman of the Board since May 30, 2007, when he succeeded Carol A. Ammon upon her retirement.  Previously, Mr. Kimmel had served as a Director since July 2000.  Mr. Kimmel had been a Director of Algos Pharmaceutical Corporation since July 1996.   Mr. Kimmel has been Vice-Chairman of Rothschild Inc., an investment banking firm, since January 2001.   Previously, he was a partner of the law firm of Latham & Watkins for more than five years.   Mr. Kimmel is also a Director of Weider Nutrition International, Inc. and Haleko, Inc., a subsidiary of Weider Nutrition International, Inc. Mr. Kimmel is chairman of Endo's Audit Committee and is a member of Endo's Nominating and Governance Committee.

Clive A. Meanwell, M.D., Ph.D. has served as a Director since January 2003. Dr. Meanwell has been the Chairman, President and Chief Executive Officer of The Medicines Company since July 2004. From September 2001 through July 2004, Dr. Meanwell was the Executive Chairman of The Medicines Company. Previously, he served as Chairman, Chief Executive Officer and President since the inception of The Medicines Company in 1996. From 1995 to 1996, Dr. Meanwell was a partner and Managing Director at MPM Capital L.P., a venture capital firm. Prior to that, he held various positions of increasing scope and responsibility at Hoffmann-La Roche, Inc. from 1986 to 1995, most recently Senior Vice President.

David P. Holveck was appointed President, Chief Executive Officer, and a Director of Endo in April 2008.  Prior to joining Endo, Mr. Holveck was President of Johnson & Johnson Development Corporation and Vice President, Corporate Development of Johnson & Johnson since 2004.  Mr. Holveck joined Johnson & Johnson as a company Group Chairman in 1999, following the acquisition of Centocor, Inc., by Johnson & Johnson.  Mr. Holveck was Chief Executive Officer of Centocor, Inc., at the time of the acquisition. Mr. Holveck joined Centocor in 1983 and progressed through various executive positions. In 1992, he assumed the role of President and Chief Operating Officer and later that year was named President and Chief Executive Officer. Prior to joining Centocor, he held positions at General Electric Company, Corning Glass Works, and Abbott Laboratories.  Mr. Holveck is a member of the Board of Trustees for the Fund for West Chester University and the Board of Directors of the Eastern Technology Council.  Effective April 7, 2008¸ Mr. Holveck was appointed to the board of directors of Light Sciences Oncology, Inc., and effective April 14, 2008, he was appointed to the board of directors of Tengion Inc.